Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation - AMLSG 15-10

niversity of Ulm0 个研究点目标入组 144 人开始时间: 2011年4月1日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Patients with confirmed diagnosis of acute myeloid leukemia according to the World Health Organization (WHO) classification (including de novo AML, t-AML and s-AML)
•- Presence of NPM1 mutation as assessed in one of the central AMLSG reference laboratories.
•- Age > 60 years. There is no upper age limit.
•- No prior chemotherapy for leukemia except hydroxyurea to control hyperleukocytosis if needed for up to 10 days during the diagnostic screening phase.
•- Signed written informed consent
•- Men must give their informed consent that they do not father a baby and must use a latex condom during any sexual contact with women of childbearing potential, even if they have undergone a successful vasectomy. (while on therapy and for 3 month after the last dose of chemotherapy)
•- WHO performance status = 3
•- Patients not eligible for intensive chemotherapy according to at least one of the following criteria:
•- HCT-CI Score >2
•- Patient's decision
•- age = 75 years

•- All other AML subtypes, in particular those AML with other recurrent genetic changes (according to WHO 2008):
•o AML with t(8;21)(q22;q22); RUNX1-RUNX1T1
•o AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
•o AML with t(15;17)(q22;q12); PML-RARA (or other translocations involving RARA)
•o AML with t(9;11)(p22;q23); MLLT3-MLL (or other translocations involving MLL)
•o AML with t(6;9)(p23;q34); DEK-NUP214
•o AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1
•- No consent for registration, storage and processing of the individual disease-characteristics and course as well as information of the family physician and all other treating physicians about study participation
•- Bleeding disorder independent of leukemia
•- Uncontrolled infection
•- Known positive for HIV, HBV or HCV
•- Organ insufficiency (creatinine >1.5x upper normal serum level; bilirubin, AST or ALP >2.5x upper normal serum level, not attributable to AML; heart failure NYHA III/IV; severe obstructive or restrictive ventilation disorder)
•- Severe neurological or psychiatric disorder interfering with ability of giving an informed consent
•- Patients with a currently active second malignancy other than non-melanoma skin cancers. Patients are not considered to have a currently active malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse within one year.

发起方

niversity of Ulm